Luo Haiqing, Li Hongjiao, Yao Na, Hu Liren, He Taiping
Center of Oncology, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, 524001, China.
Tumour Biol. 2014 Jun;35(6):5823-32. doi: 10.1007/s13277-014-1772-9. Epub 2014 Mar 6.
Metastasis-associated protein 1 (MTA1) is a molecular marker in various solid tumors that has recently been investigated. The prognostic significance of MAT1 expression remains controversial. In this work, we aimed to determine the relationship between immunohistochemistry-detected MAT1 expression and survival of patients with solid tumors by conducting a meta-analysis of cohort studies. Relevant studies were identified via an electronic database search updated on October 28, 2013. We included cohort studies that reported hazard ratios (HRs) or odds ratios (ORs) with 95 % confidence intervals (CIs) to determine the association of high MTA1 expression with overall survival (OS) and clinicopathological characteristics. Heterogeneity was quantified using I (2) statistics, and publication bias was evaluated using funnel plots. Sensitivity analysis was conducted to evaluate the robustness of meta-analysis findings. We identified 16 cohort studies that focused on MTA1 overexpression and prognosis involving 2,253 cancer patients. Overall, the combined HR for OS was 1.85 (95 % CI: 1.55-2.28, P<0.001). Omission of any single study had no significant effect on the pooled HR estimate. When the studies were stratified by tumor type, similar results of poor prognosis were observed in non-small cell lung cancer (HR=2.05, 95 % CI: 1.14-3.68, P=0.016) and esophageal squamous cell carcinoma (HR=1.86, 95 % CI: 1.44-2.39, P<0.001). Moreover, multivariate survival analysis showed that MTA1 overexpression was an independent predictor of poor prognosis (HR=1.90, 95 % CI: 1.53-2.37, P<0.001). In addtional, MTA1 overexpression was significantly associated with tumor size (OR=2.72, 95 % CI=1.44-5.14, P=0.002), tumor stage (OR=2.44, 95 % CI=1.67-3.57, P<0.001), depth of invasion (OR=2.63, 95 % CI=1.74-3.97, P<0.001), and lymph node metastasis (OR=2.57, 95 % CI=1.57-4.19, P<0.001). However, when age, sex, and tumor differentiation were considered, no obvious association was observed. This study provides a comprehensive examination of the literature available on the association of MTA1 overexpression with OS and some clinicopathological features in solid tumors. Meta-analysis results provide evidence that MTA1 may be a new indicator of poor cancer prognosis. Considering the limitations of the eligible studies, other large-scale prospective trials must be conducted to clarify the prognostic value of MTA1 in predicting cancer survival.
转移相关蛋白1（MTA1）是最近被研究的多种实体瘤中的一种分子标志物。MTA1表达的预后意义仍存在争议。在本研究中，我们旨在通过对队列研究进行荟萃分析，确定免疫组织化学检测到的MTA1表达与实体瘤患者生存之间的关系。通过对2013年10月28日更新的电子数据库进行检索，确定了相关研究。我们纳入了报告风险比（HRs）或比值比（ORs）及95%置信区间（CIs）的队列研究，以确定MTA1高表达与总生存期（OS）及临床病理特征之间的关联。使用I²统计量对异质性进行量化，并使用漏斗图评估发表偏倚。进行敏感性分析以评估荟萃分析结果的稳健性。我们确定了16项关注MTA1过表达与预后的队列研究，涉及2253例癌症患者。总体而言，OS的合并HR为1.85（95%CI：1.55 - 2.28，P < 0.001）。省略任何一项研究对汇总HR估计值均无显著影响。当按肿瘤类型进行分层时，在非小细胞肺癌（HR = 2.05，95%CI：1.14 - 3.68，P = 0.016）和食管鳞状细胞癌（HR = 1.86，95%CI：1.44 - 2.39，P < 0.001）中观察到类似的预后不良结果。此外，多因素生存分析表明MTA1过表达是预后不良的独立预测因素（HR = 1.90，95%CI：1.53 - 2.37，P < 0.001）。另外，MTA1过表达与肿瘤大小（OR = 2.72，95%CI = 1.44 - 5.14，P = 0.002）、肿瘤分期（OR = 2.44，95%CI = 1.67 - 3.57，P < 0.001）、浸润深度（OR = 2.63，95%CI = 1.74 - 3.97，P < 0.001）和淋巴结转移（OR = 2.57，95%CI = 1.57 - 4.19，P < 0.001）显著相关。然而，在考虑年龄、性别和肿瘤分化时，未观察到明显关联。本研究全面审查了关于MTA1过表达与实体瘤OS及一些临床病理特征关联的现有文献。荟萃分析结果提供了证据表明MTA1可能是癌症预后不良的一个新指标。考虑到纳入研究的局限性，必须进行其他大规模前瞻性试验以阐明MTA1在预测癌症生存方面的预后价值。
